Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak ( for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 17, Number 4, 2012

Should the prescription of oral anticancer drugs be restricted?

Alfredo Ramos, José Lopez Torrecilla, Pedro Lara, Ismael Herruzo, Jorge Contreras, Ana Mañas, Ferran Guedea, on behalf of the board of directors of the Spanish Society of Radiation Oncology (SEOR)


1. Introduction

In the year 2010, the Spanish Society of Medical Oncology (SEOM) published an editorial1 in the Annals of Oncology entitled “Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology”. The main premise of the editorial was a call to grant medical oncologists the exclusive right to prescribe all anticancer drugs, whether administration is intravenous or oral. As might be expected, that editorial has ignited a fierce and ongoing debate in Spain.

The first medical society to respond was the Spanish Society of Radiation Oncologists (SEOR) via a letter to the editor2 to rebut the radical stance taken by the SEOM. The SEOR also followed up that letter with an editorial in the Spanish journal Clinical and Translational Oncology (CTO).3 Several months later, endocrinologists representing the Spanish Society of Endocrinology and Nutrition (SEEN) also responded to the original SEOM editorial with a letter to the editor of Annals of Oncology.4

We believe that the outcome of this intense debate, which is taking place in a well-known international journal, has implications for all specialists who currently prescribe oral anticancer medications.

Signature: Rep Pract Oncol Radiother, 2012; 17(4) : 187-189

« back


Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.